strontium/kansè

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 129 rezilta yo

Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Giant Cell Tumors of Bone (GCTB) are benign but aggressive and metastatic tumors. Surgical removal cannot eradicate GCTB due to the subsequent recurrence and osteolysis. Here we developed Zoledronic acid (ZA)-loaded magnesium-strontium (Mg-Sr) alloys that can inhibit GCTB and studied the molecular

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Bony metastatic castration-refractory prostate cancer is associated with a poor prognosis and high morbidity. TRAPEZE was a two-by-two factorial randomised controlled trial of zoledronic acid (ZA) and strontium-89 (Sr-89), each combined with docetaxel. All have palliative benefits, are used to

Radiation-induced meningeal and pituitary tumors in the rat after prenatal application of strontium-90.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Strontium-90 was inject i.v. into pregnant rats on day 18 post conception (p.c.). This caused a remarkable transplacental radioactivity uptake and accumulation in the ossification centers of the skull basis. The total radiation dose within the surface of these regions was consequently calculated to

Strontium-89 for treatment of painful bone metastasis from prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To review the current use of strontium-89 (89Sr) to treat pain related to bony metastasis secondary to prostate cancer. METHODS Published articles. RESULTS Prostate cancer is the most commonly diagnosed cancer in the United States. The disease's most common site of metastasis is the bones.

Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The aim of the present study was to evaluate the palliative effects and adverse events of strontium-89 (Sr-89) in patients with bone metastasis from prostate cancer. A total of 18 patients with prostate cancer and painful bone metastases, as diagnosed on bone scintigraphy, who were treated with

Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE In a prospective randomized Canadian trial, addition of radionuclide strontium (89Sr) to external radiotherapy (ER) was found to prolong the time to further ER by 15 weeks (35 versus 20, P = 0.006) compared to ER alone in patients with hormone-refractory metastatic prostate cancer (HRMPC).

[A multicenter study to determine the efficacy and safety of strontium (89Sr) chloride for palliation of painful bony metastases in cancer patients].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE A multicenter study was conducted to evaluate the efficacy of strontium chloride (89SrCl2) for palliation of painful bony metastases using the Visual Analogue Scale (VAS), Brief Pain Inventory (BPI) and Functional Assessment for Cancer Therapy-General (FACT-G). METHODS Ninety patients

Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We investigated the activity of a bone-targeting regimen consisting of strontium-89 and doxorubicin in the treatment of patients with androgen-independent prostate cancer. Three and 22 patients with androgen-independent prostate cancer and bone metastasis received doxorubicin at 15 mg/m(2) and 20

Strontium Sulfite: A New pH-Responsive Inorganic Nanocarrier to Deliver Therapeutic siRNAs to Cancer Cells.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Inorganic nanoparticles hold great potential in the area of precision medicine, particularly for treating cancer owing to their unique physicochemical properties, biocompatibility and improved pharmacokinetics properties compared to their organic counterparts. Here we introduce strontium sulfite

Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The palliation of bone pain is a common clinical problem once metastatic prostate cancer has escaped from hormonal control. This retrospective study compares the results of treatment using hemibody irradiation (HBI) at the Royal Marsden Hospital (27 cases) with isotope therapy using the bone-seeking

Aptamer-capped multifunctional mesoporous strontium hydroxyapatite nanovehicle for cancer-cell-responsive drug delivery and imaging.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A novel cancer-cells-triggered controlled-release gadolinium-doped luminescent and mesoporous strontium hydroxyapatite nanorods (designated as Gd:SrHap nanorods) system using cell-type-specific aptamers as caps has been constructed. Aptamers behave as a dual-functional molecule that acts as not only

[Effectiveness of Strontium-89 for Neuropathic Pain Caused by Bone Metastases from Breast Cancer: A Case Report].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The patient was a 47-year-old female with stage IV breast cancer and multiple bone metastases. She received various systemic therapies (hormone therapy and chemotherapy) and underwent mastectomy between 2013 and 2018; in the beginning of 2018, she started experiencing bone metastatic pain in the

Preconcentration of Lead in Blood and Urine Samples Among Bladder Cancer Patients Using Mesoporous Strontium Titanate Nanoparticles.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In this work, mesoporous strontium titanate nanoparticles (SrTiO₃ NPs) were synthesized through a single-step combustion process and were characterized by FT-IR, XRD, SEM-EDX, and TEM. The effects of main parameters that may influence the extraction process (i.e., pH, sorbent amount, time

A patient with esophageal cancer with bone metastasis who achieved pain relief with repetitive administration of strontium-89 chloride.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 75-year-old woman was diagnosed with esophageal cancer with difficulty in swallowing. She had a past history of rheumatoid arthritis, scleroderma, interstitial pneumonia, angina pectoris (with coronary artery bypass surgery) and arrhythmia (with pacemaker implantation). She refused surgery, and

[Phase II clinical trial of the radioactive strontium (89Sr) chloride agent, SMS. 2P for pain palliation in patients with prostate cancer with bone metastases].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The phase II clinical trial of a strontium (89Sr) chloride agent (SMS. 2P) was performed in 9 patients with painful bone metastases secondary to prostate cancer. After an intravenous administration, 89Sr circulated in the plasma and was rapidly cleared. Urinary excretion varied widely among the

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye